

[For Immediate Release]



## **TUL Receives Drug Registration Approval for Insulin Aspart** *Enriching Portfolio of Diabetic Drugs*

(15 July 2021 - Hong Kong) **The United Laboratories International Holdings Limited** (“TUL”, the “Company” or the “Group”; Stock code: 3933), one of the leading pharmaceutical product manufacturers in the PRC, is pleased to announce that on 12 July 2021, the insulin aspart injection and insulin aspart 30 injection that applied by the Group, have passed the drug registration approval of National Medical Products Administration. Both the approved insulin aspart injection and insulin aspart 30 injection include two specifications, being 3ml: 300U (refilled pen-type) and 3ml: 300U (disposable pen-type).

Insulin aspart injection and insulin aspart 30 injection are developed as the treatment of diabetes. Insulin aspart is a fast-acting insulin analogue, and it can be administered by subcutaneously injection and insulin pump infusion. Compared with soluble human insulin, insulin aspart is characterized by both rapid onset of action and high safety, and is able to improving postprandial glucose excursions significantly. It is a relatively important mealtime insulin in the diabetes treatment. Insulin aspart 30 is a premixed insulin analogue consisting of 30% soluble insulin aspart and 70% protamine insulin aspart. Compared with recombinant human insulin 30R, insulin aspart 30 is characterized by a faster onset of action, which can better control postprandial glucose excursions and lower risk of hypoglycemia. It has a significant advantage in improving patient compliance.

According to the report statistics from the International Diabetes Federation in 2019, the number of diabetic patients in China was approximately 116 million, representing a huge market demand for diabetes treatment drugs. In terms of market size, according to IMS Health Inc., the sales amount of drugs for diabetes treatment in China was approximately US\$3,921 million in 2019, up 8.97% year on year.

**Mr. Tsoi Hoi Shan, Chairman of the Group** stated, “The Group sees diabetes drugs as its strategic focus, and devotes itself to the research and development of new products and enriching the product pipeline of diabetes drugs in order to enhance its competitiveness in the biopharmaceutical industry. The insulin aspart injection and insulin aspart 30 injection successfully passing the drug registration approval will further consolidate the Group’s market position in the diabetes drugs. The Group will proactively seize the first-mover advantage, optimize the deployment of sales team and marketing strategy and launch the new products as soon as possible, so as to provide patients with more safe and efficient treatment choices and maximize the value for our shareholders.”

– End –

**Company Information**

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading comprehensive pharmaceutical companies in China, principally engaged in the R&D, manufacturing and selling of finished products, bulk medicines and intermediate products. The Group has six production bases, and its sales teams for intermediate products, bulk medicines and finished products formed a broad sales network covering China and the rest of the world. Currently, TUL is one of the few pharmaceutical companies in China that owns both second and third generation insulin products. The Group is presently a component of the Hang Seng Composite Index Series.

**For further enquiries, please contact:**

**iPR Ogilvy Ltd.**

Tina Law / Joann Fang

Tel: (852) 2136 6181 / 3920 7619

Fax: (852) 3170 6606

Email: [tul@iprogilvy.com](mailto:tul@iprogilvy.com)